Lucid Diagnostics Inc LUCD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
-
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
-
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
-
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
-
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
-
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Trading Information
- Previous Close Price
- $1.02
- Day Range
- $0.95–1.03
- 52-Week Range
- $0.90–1.63
- Bid/Ask
- $0.95 / $1.00
- Shares Outstanding
- 190.77M
- Market Cap
- $181.27M
- Volume/Avg
- 3M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 82
- Website
- https://www.luciddx.com
Valuation
|
Metric
|
LUCD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 22.17 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LUCD
|
|---|---|
Quick Ratio | 0.97 |
Current Ratio | 1.07 |
Interest Coverage | −2,269.10 |
Quick Ratio
LUCD
Profitability
|
Metric
|
LUCD
|
|---|---|
Return on Assets (Normalized) | −113.21% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −124.22% |
Return on Assets
LUCD
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|z%m<SG? | LOCK|v&pw | $175B | |||
| Stryker Corp
SYK
| LOCK|<nYDrG<^ | LOCK|@r | $123B | |||
| Medtronic PLC
MDT
| LOCK|bW^!l> | LOCK|kg@@ | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|M^pGFz | LOCK|qH$# | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|>@X<%&m | LOCK|^#tGK | $49B | |||
| DexCom Inc
DXCM
| LOCK|#z&P&%xk | LOCK|hRVG! | $30B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|#<@^$x> | LOCK|>^ | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|>j | LOCK|x^& | $26B | |||
| Steris PLC
STE
| LOCK|tvrdTC! | LOCK|X#^w& | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|<&><^^h | LOCK|k^ | $18B |
United States